May.14 — Novavax Inc.’s vaccine is one of at least 100 potential candidates trying to curb the spread of the virus that causes Covid-19. The biotech company recently received a funding of $388-million from the Coalition for Epidemic Preparedness Innovation, making it the biggest investment ever from the group. Dr. Gregory Glenn, Novavax’s president of research and development, speaks on “Bloomberg Technology.”
source
Tradepoint.io, being just a publishing and technology platform, is not a registered broker-dealer or investment adviser. So we do not provide investment advice. Rather, brokerage services are provided to clients of Tradepoint.io by independent SEC-registered broker-dealers and members of FINRA/SIPC. Every form of investing carries some risk and past performance is not a guarantee of future results. “Tradepoint.io“, “Instant Investing” and “My Trading Tools” are registered trademarks of Apperbuild, LLC.
This website is operated by Apperbuild, LLC. We have no link to any brokerage firm and we do not provide investment advice. Every information and resource we provide is solely for the education of our readers. © 2020 Apperbuild, LLC. All rights reserved.